摘要
目的总结重组人粒细胞－集落刺激因子（ｒｈＧ－ＣＳＦ）预防肺癌化疗期感染的效果。方法回顾分析１６３例（３０８例次）肺癌患者化疗期辅用或不用ｒｈＧ－ＣＳＦ中性粒细胞恢复和感染情况。结果化疗期用ｒｈＧ－ＣＳＦ患者（Ｇ－ＣＳＦ组）感染率（５４／２１７，２５％）明显低于非Ｇ－ＣＳＦ组（５１／９１，５６％）（Ｐ＜０．００５）；Ｇ－ＣＳＦ组化疗期中性粒细胞减少的发生率明显低于非Ｇ－ＣＳＦ组（Ｐ＜０．００５），并且Ｇ－ＣＳＦ组中性粒细胞减少（＜１．０×１０９·Ｌ－１）持续时间（３天）比非Ｇ－ＣＳＦ组（４天）缩短一天（Ｐ＜０．００１）。但两组感染治疗效果差异无显著性（Ｐ＞０．０５）。结论ｒｈＧ－ＣＳＦ通过促进中性粒细胞增殖，缩短化疗期中性粒细胞减少持续时间，不仅能增加肺癌患者对化疗的耐受性，而且还能预防化疗期感染，同时又可提高患者的生活质量。
Objective To recognize the prophylactic effect of rhG CSF used on infection complications secondary to chemotherapy in patients with lung cancer. Method The infection complications and the neutropenia secondary to chemotherapy in 163 cases of lung cancer patients with or without rhG CSF were retrospectively analyzed. Result RhG CSF administration reduced the frequency of infection complications, and there was a significant difference( P <0.005) in the frequency of infection between the G CSF group's patients (infections incidence 25%) and non G CSF group's (56%). The incidence of neutropenia in G CSF group' patients is obviously less than that in non G CSF group's ( P <0.005). The median number of days of the neutropenia (neutrophil count of <1.0×10 9)in G CSF group(3 days) is less than that in non G CSF group(4 days)( P <0.001). However, there was no significant difference ( P >0.05) between G CSF group(63%) and non G CSF group(76%) in terms of response of the infection complications. Conclusion Our data has shown that the administration of rhG CSF as an adjunct to chemotherapy in patients with lung cancer can accelerate neutrophil recovery and shorten the duration of neutropenia , and lead to reductions in the incidence of infection complications, and also has the potential to increase the amount of cytotoxic chemotherapy and the quantity of life.
出处
《中华结核和呼吸杂志》
CAS
CSCD
北大核心
1998年第6期355-357,共3页
Chinese Journal of Tuberculosis and Respiratory Diseases
关键词
肺肿瘤
RHG-CSF
药物疗法
预防
Recombinant human gyanulocyte colony stimulating factor Lung neoplasma Chemotherapy Infection
